Diagnosis and therapy in ovarian hyperstimulation syndrome;Diagnostik und Therapie beim ovariellen Hyperstimulationssyndrom

Gynakologe

Volumn 29, Issue 4, 1996, Pages 300-307

  Graf, M ^a   Fischer, R ^a  

^a Institut fur Hormon und Fortpflanzungsforschung IHF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHORIONIC GONADOTROPIN; DEXTRAN; DIURETIC AGENT; DOPAMINE; HETASTARCH; HUMAN MENOPAUSAL GONADOTROPIN; METHOTREXATE;

DISEASE CLASSIFICATION; FEMALE; HUMAN; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

EID: 0030011528     PISSN: 00175994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Aboulghar MA, Mansour RT, Serour GI, Sattar MA, Amin YM, Elattar I (1993) Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol 81: 108-111
2. Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC (1991) Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 6: 1395-1399
3. Asch RH, Ivery G, Goldsman M, Frederick JL, Stone SC, Balmaceda JP (1993) The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod 8: 1015-1020
4. Asch RH (1994) Letter to the Editor. Hum Reprod 9: 753-754
5. Ayhan A, Urman B, Gurgan T, Tuncer ZS, Deren O (1993) Thrombosis of the internal jugular vein associated with severe ovarian hyperstimulation syndrome. Aust N Z J Obstet Gynaecol 33: 436-437
6. Balasch J, Tur R, Creus M et al. (1994) Triggering of ovulation by a gonadotropin releasing hormone agonist in gonadotropin-stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy. Gynecol Endocrinol 8: 7-12
7. Bar-Hava I, Homburg R (1993) Correct timing of administration of diuretic agents for the treatment of ovarian hyperstimulation syndrome. Gynecol Endocrinol 7: 63-65
8. Belaisch-Allart J, Belaisch J, Hazout A, Te-start J, Frydman R (1988) Selective oocyte retrieval: a new approach to ovarian hyperstimulation. Fertil Steril 50: 654-656
9. Bider D, Menashe Y, Oelsner G, Serr DM, Mashiach S, Ben-Rafael Z (1989) Ovaran hyperstimulation syndrome due to exogenous gonadotropin administration. Acta Obstet Gynecol Scand 68: 511-514
10. Blankstein J, Shalev J, Saadon T et al. (1987) Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril 47: 597-602
11. Brock TA, Dvorak HF, Senger DR (1991) Tumor secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 138: 213-221
12. Clauss M, Gerlach M, Gerlach H et al. (1990) Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration. J Exp Med 172: 1535-1545
13. Donderwinkel PF, van der Meer S, Dorr JP (1994) Methotrexate in management of advanced ectopic pregnancy complicated by ovarian hyperstimulation syndrome. Acta Obstet Gynecol Scand 73: 753-754
14. Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, Trounson A (1992) Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 7: 180-183
15. Fukaya T, Chida S, Terada Y, Funayama Y, Yajima A (1994) Treatment of severe ovarian hyperstimulation syndrome by ultrafiltration and reinfusion of ascitic fluid. Fertil Steril 61: 561-564
16. Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH (1995) Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome Fertil Steril 63: 268-272
17. Homburg R, Levy T, Ben Rafael Z (1995) A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 63: 729-733
18. Itskovitz-Eldor J, Levron J, Kol S (1993) Use of gonadotropin-releasing hormone agonist to cause ovulation and prevent the ovarian hyperstimuiation syndrome. Clin Obstet Gynecol 36: 701-710
19. Jaffe SB, Jaffe LH, Jewelewicz R (1993) Incidence of severe ovarian hyperstimulation syndrome with extremely elevated serum estrogen levels. Gynecol Obstet Invest 35: 222-227
20. Keck C, Neulen J, Breckwoldt M (1994) Das ovarielle Hyperstimulationssyndrom. Geburtshilfe Frauenheilkd 54: 315-320
21. Kleinstein J (1991) Das Hyperstimulationssyndrom. Gynäkologe 24: 130-135
22. Kushnir O, Ben-Rafael Z, Shalev J, Lipitz S, Bider D, Mashiach S, Blankstein J (1991) Hormonal profiles and follicular growth in cycles with imminent ovarian hyperstimulation. Hum Reprod 6: 665-669
23. Lanzone A, Fulghesu AM, Villa P et al. (1994) Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. Fertil Steril 62: 35-41
24. Mills MS, Eddowes HA, Fox R, Wardle PG (1992) Subclavian vein thrombosis: a late complication of ovarian hyperstimulation syndrome. Hum Reprod 7: 370-371
25. Morris RS, Paulson RJ (1994) Letter to the Editor: Does intravenous albumin prevent ovarian hyperstimulation syndrome? Hum Reprod 9: 753
26. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosler A, Schenker JG (1987) Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 48: 57-61
27. Navot D, Bergh PA, Laufer N (1992) Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 58: 249-261
28. Neulen J, Yan Z, Raczek S et al. (1995) Ovarian hyperstimulation syndrome: vascular endothelial growth factor/vascular permeability factor from luteinized granulosa cells is a pathophysiological principle. Hum Reprod 10/2: [Abstract 5]
29. Ng E, Leader A, Claman P, Domingo M, Spence JEH (1995) Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. Hum Reprod 10: 807-810
30. Oppenheim JJ, Ruscetti FW, Faltynek C (1991) Cytokines. In: Stites DP, Terr AI (eds) Basic and clinical immunology, 7. edn. Appleton & Lange, East Norwalk, CT, p 78
31. Orvieto R, Voliovitch I, Fishman P, Ben-Rafael Z (1995) Interleukin-2 and ovarian hyperstimulation syndrome: a pilot study. Hum Reprod 10: 24-27
32. Orvieto R, Dekel A, Dicker D, Bar-Hava I, Ben-Rafael Z (1995) A severe case of ovarian hyperstimulation syndrome despite the prophylactic administration of intravenous albumin. Fertil Steril 64: 860-862
33. Peces R, Escalada P, Sánchez-Fructuoso A, de la Torre M (1994) Treatment of prerenal azotaemia associated with severe ovarian hyperstimulation syndrome. Nephrol Dial Transplant 9: 326-328
34. Rabau E, David A, Serr DM, Mashiach S, Lunenfeld, B (1967) Human menopausal gonadotropins for anovulation and sterility. Am J Obstet Gynecol 96: 92-98
35. Rabinovici J, Kushnir O, Shalev J, Goldenberg M, Blankstein J (1987) Rescue of menotropin cycles prone to develop ovarian hyperstimulation. Br J Obstet Gynaecol 94: 1098-1102
36. Rotmensch S, Scommegna A (1989) Spontaneous ovarian hyperstimulation syndrome associated with hypothyroidism. Am J Obstet Gynecol 160: 1220-1222
37. Schenker JG, Weinstein D (1978) Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 30: 255-268
38. Shalev E, Giladi Y, Matilsky M, Ben-Ami M (1995) Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: A prospective study. Hum Reprod 10: 1373-1376
39. Sher G, Zouves C, Feinmann M, Maassarani G (1995) "Prolonged coasting": an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Hum Reprod 10: 3107-3109
40. Shoham Z, Weissman A, Barash A, Borenstein R, Schachter M, Insler V (1994) Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: A prospective, randomized, placebo-controlled study. Fertil Steril 62: 137-142
41. Splendiani G, Mazzarella V, Tozzo C, Elli M, Casciani CU (1994) Autologous protein reinfusion in severe ovary hyperstimulation syndrome. J Am Coll Surg 179: 25-28
42. Tan S-L, Balen A, Hussein EE, Campbell S, Jacobs HS (1992) The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study. Fertil Steril 58: 378-383
43. Wada I, Matson PL, Troup SA, Morroll DR, Hunt L, Lieberman BA (1993) Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition? Br J Obstet Gynaecol 100: 265-269
44. WHO (1973) Agents stimulating gonadal function in human. World Health Organ Tech Rep Ser 514
45. Yaron Y, Lessing JB, Peyser MR (1995) Expectant management of ectopic pregnancy in the presence of ovarian hyperstimulation syndrome. Acta Obstet Gynecol Scand 74: 80-81
46. Zalel Y, Katz Z, Caspi B, Ben-Hur H, Dgani R, Insler V (1992) Spontaneous ovarian hpyerstimulation syndrome concomitant with spontaneous pregnancy in a woman with polycystic ovary disease. Am J Obstet Gynecol 167: 122-124
47. Zalel Y, Orvieto R, Ben-Rafael Z, Homburg R, Fisher O, Insler V (1995) Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome. Gynecol Endocrinol 9: 313-315
48. Zosmer A, Katz Z, Lancet M, Komchezky S, Schwartz-Shoham Z (1987) Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril 47: 524-526